| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 13.1124 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 13.1124. The average price that 2413.T shares were previous bought at was JPY 14.2974. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 986 (USD $6) compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.4903 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.4903. The average price that 4151.T shares were previous bought at was JPY 15.9178. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in 4151.T has fallen by JPY 21,492 (USD $139) compared to the previous valuation of Kyowa Kirin Co., Ltd. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.8885 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.8885. The average price that 4502.T shares were previous bought at was JPY 28.8244. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in 4502.T has fallen by JPY 10,898 (USD $70) compared to the previous valuation of Takeda Pharmaceutical Company Limited |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 13.5725 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 13.5725. The average price that 4503.T shares were previous bought at was JPY 11.3001. The current market price is 20.1% higher than average price they were purchased at. The value of the holding in 4503.T has fallen by JPY 88,327 (USD $571) compared to the previous valuation of Astellas Pharma Inc. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 17.494 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 17.494. The average price that 4507.T shares were previous bought at was JPY 17.0705. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in 4507.T has fallen by JPY 6,054 (USD $39) compared to the previous valuation of Shionogi & Co., Ltd. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 52.6106 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 52.6106. The average price that 4519.T shares were previous bought at was JPY 47.9773. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in 4519.T has fallen by JPY 69,838 (USD $451) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 29.0558 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 29.0558. The average price that 4523.T shares were previous bought at was JPY 30.3171. The current market price is -4.2% lower than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 87,493 (USD $565) compared to the previous valuation of Eisai Co., Ltd. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 14.8818 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 14.8818. The average price that 4543.T shares were previous bought at was JPY 16.204. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in 4543.T has fallen by JPY 2,659 (USD $17) compared to the previous valuation of Terumo Corporation |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 22.2744 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 22.2744. The average price that 4568.T shares were previous bought at was JPY 23.7402. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in 4568.T has increased by JPY 68,061 (USD $440) compared to the previous valuation of Daiichi Sankyo Company, Limited however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 59.3791 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 59.3791. The average price that 4578.T shares were previous bought at was JPY 54.7568. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 715 (USD $5) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.79572 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.79572. The average price that 6869.T shares were previous bought at was JPY 11.7732. The current market price is -16.8% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 12,140 (USD $78) compared to the previous valuation of Sysmex Corporation |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.8519 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.8519. The average price that 7733.T shares were previous bought at was JPY 12.7389. The current market price is 0.9% higher than average price they were purchased at. The value of the holding in 7733.T has fallen by JPY 3,650 (USD $24) compared to the previous valuation of Olympus Corporation |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 153.064 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 153.064. The average price that 7741.T shares were previous bought at was JPY 145.997. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in 7741.T has fallen by JPY 23,616 (USD $153) compared to the previous valuation of HOYA Corporation |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 136.66 | USD 0 | The current share valuation price of A based on adjusted close was USD 136.66. The average price that A shares were previous bought at was USD 135.825. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in A has fallen by USD 147,276 compared to the previous valuation of Agilent Technologies Inc |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 224.31 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 224.31. The average price that ABBV shares were previous bought at was USD 208.53. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 98,519 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 126.71 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 126.71. The average price that ABT shares were previous bought at was USD 131.201. The current market price is -3.4% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 13,876 compared to the previous valuation of Abbott Laboratories |
| ALC.SW - | HOLD | 0 @ CHF 79.7432 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 79.7432. The average price that ALC.SW shares were previous bought at was CHF 78.0142. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 154,026 (USD $193,695) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 392.1 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 392.1. The average price that ALNY shares were previous bought at was USD 419.366. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in ALNY has increased by USD 10,356 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 326.01 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 326.01. The average price that AMGN shares were previous bought at was USD 304.386. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in AMGN has fallen by USD 28,098 compared to the previous valuation of Amgen Inc |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 875.475 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 875.475. The average price that ARGX.BR shares were previous bought at was EUR 849.201. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 97,889 (USD $115,015) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 181.617 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 181.617. The average price that AZN.L shares were previous bought at was GBP 163.985. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 64,952 (USD $87,198) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 19.29 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 19.29. The average price that BAX shares were previous bought at was USD 19.4921. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 3,924 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 41.2642 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 41.2642. The average price that BAYN.DE shares were previous bought at was EUR 33.6975. The current market price is 22.5% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 93 (USD $109) compared to the previous valuation of Bayer AG however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 195.36 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 195.36. The average price that BDX shares were previous bought at was USD 185.934. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in BDX has fallen by USD 6,452 compared to the previous valuation of Becton Dickinson and Company |
| BIIB - Biogen Inc | HOLD | 0 @ USD 172.1 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 172.1. The average price that BIIB shares were previous bought at was USD 173.989. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in BIIB has increased by USD 5,734 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 127.536 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 127.536. The average price that BIM.PA shares were previous bought at was EUR 126.886. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in BIM.PA has increased by EUR 3,308 (USD $3,887) compared to the previous valuation of BioMerieux however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 53.55 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 53.55. The average price that BMY shares were previous bought at was USD 47.8225. The current market price is 12.0% higher than average price they were purchased at. The value of the holding in BMY has fallen by USD 89,630 compared to the previous valuation of Bloomsbury Publishing Plc |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 94.48 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 94.48. The average price that BSX shares were previous bought at was USD 99.851. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 54,156 compared to the previous valuation of Boston Scientific Corporation however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 94.48 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 94.48. The average price that BSX shares were previous bought at was USD 99.851. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in BSX has increased by USD 54,156 compared to the previous valuation of MULSTRXSSXIMETFP however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 198.44 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 198.44. The average price that CAH shares were previous bought at was USD 173.314. The current market price is 14.5% higher than average price they were purchased at. The value of the holding in CAH has increased by USD 28,399 compared to the previous valuation of Cardinal Health Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| CI - Cigna Corp | HOLD | 0 @ USD 273.84 | USD 0 | The current share valuation price of CI based on adjusted close was USD 273.84. The average price that CI shares were previous bought at was USD 287.41. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 87,397 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.87 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.87. The average price that CNC shares were previous bought at was USD 38.5786. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in CNC has fallen by USD 9,835 compared to the previous valuation of Concurrent Technologies Plc |
| COH.AX - | HOLD | 0 @ AUD 171.099 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 171.099. The average price that COH.AX shares were previous bought at was AUD 183.354. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 59,469 (USD $39,452) compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 86.3683 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 86.3683. The average price that COLO-B.CO shares were previous bought at was DKK 91.1232. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in COLO-B.CO has fallen by DKK 28,286 (USD $4,449) compared to the previous valuation of |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 82.48 | USD 0 | The current share valuation price of COO based on adjusted close was USD 82.48. The average price that COO shares were previous bought at was USD 76.0493. The current market price is 8.5% higher than average price they were purchased at. The value of the holding in COO has increased by USD 28,561 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 342.96 | USD 0 | The current share valuation price of COR based on adjusted close was USD 342.96. The average price that COR shares were previous bought at was USD 325.675. The current market price is 5.3% higher than average price they were purchased at. The value of the holding in COR has increased by USD 48,156 compared to the previous valuation of Cencora Inc. however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| CSL.AX - | HOLD | 0 @ AUD 114.637 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 114.637. The average price that CSL.AX shares were previous bought at was AUD 120.066. The current market price is -4.5% lower than average price they were purchased at. The value of the holding in CSL.AX has fallen by AUD 81,386 (USD $53,991) compared to the previous valuation of |
| CVS - CVS Health Corp | HOLD | 0 @ USD 77.88 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 77.88. The average price that CVS shares were previous bought at was USD 71.7416. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in CVS has fallen by USD 32,567 compared to the previous valuation of CVS Health Corp |
| DEMANT.CO - | HOLD | 0 @ DKK 33.1944 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.1944. The average price that DEMANT.CO shares were previous bought at was DKK 35.2897. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 18,800 (USD $2,957) compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 179.1 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 179.1. The average price that DGX shares were previous bought at was USD 181.03. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in DGX has increased by USD 1,060 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 222.63 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 222.63. The average price that DHR shares were previous bought at was USD 211.186. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 101,840 compared to the previous valuation of Danaher Corporation |
| DHR - Danaher Corporation | HOLD | 0 @ USD 222.63 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 222.63. The average price that DHR shares were previous bought at was USD 211.186. The current market price is 5.4% higher than average price they were purchased at. The value of the holding in DHR has fallen by USD 101,840 compared to the previous valuation of Danaher Corporation |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 239.675 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 239.675. The average price that DIM.PA shares were previous bought at was EUR 223.9. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in DIM.PA has fallen by EUR 8,137 (USD $9,561) compared to the previous valuation of Sartorius Stedim Biotech |
| DXCM - DexCom Inc | HOLD | 0 @ USD 65.75 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 65.75. The average price that DXCM shares were previous bought at was USD 68.9681. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in DXCM has fallen by USD 7,639 compared to the previous valuation of DexCom Inc |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 321.721 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 321.721. The average price that EL.PA shares were previous bought at was EUR 342.345. The current market price is -6.0% lower than average price they were purchased at. The value of the holding in EL.PA has fallen by EUR 138,333 (USD $162,534) compared to the previous valuation of EssilorLuxottica SA |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 345.96 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 345.96. The average price that ELV shares were previous bought at was USD 338.366. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in ELV has fallen by USD 217,648 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 345.96 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 345.96. The average price that ELV shares were previous bought at was USD 338.366. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in ELV has fallen by USD 217,648 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 69.6571 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 69.6571. The average price that ERF.PA shares were previous bought at was EUR 69.0799. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in ERF.PA has increased by EUR 4,658 (USD $5,473) compared to the previous valuation of Eurofins Scientific SE however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 84.84 | USD 0 | The current share valuation price of EW based on adjusted close was USD 84.84. The average price that EW shares were previous bought at was USD 80.0235. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 48,458 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.3706 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.3706. The average price that FME.DE shares were previous bought at was EUR 49.9034. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in FME.DE has increased by EUR 463 (USD $544) compared to the previous valuation of Fresenius Medical Care AG however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| FPH.NZ - | HOLD | 0 @ NZD 21.5436 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 21.5436. The average price that FPH.NZ shares were previous bought at was NZD 21.3251. The current market price is 1.0% higher than average price they were purchased at. The value of the holding in FPH.NZ has fallen by NZD 5,157 (USD $2,984) compared to the previous valuation of |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 56.163 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 56.163. The average price that FRE.DE shares were previous bought at was EUR 53.0548. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 3,350 (USD $3,936) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 204.267 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 204.267. The average price that GALD.SW shares were previous bought at was CHF 186.072. The current market price is 9.8% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 5,549 (USD $6,978) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 82.38 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 82.38. The average price that GEHC shares were previous bought at was USD 77.1977. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 1,333 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 121.36 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 121.36. The average price that GILD shares were previous bought at was USD 117.192. The current market price is 3.6% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 397,387 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 317.628 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 317.628. The average price that GMAB.CO shares were previous bought at was DKK 286.791. The current market price is 10.8% higher than average price they were purchased at. The value of the holding in GMAB.CO has increased by DKK 63,621 (USD $10,006) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.5479 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.5479. The average price that GRF.MC shares were previous bought at was EUR 13.0441. The current market price is -3.8% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 3,833 (USD $4,504) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.568 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.568. The average price that GSK.L shares were previous bought at was GBP 23.3517. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 35,320 (USD $47,417) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 471.85 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 471.85. The average price that HCA shares were previous bought at was USD 448.598. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in HCA has increased by USD 8,609 compared to the previous valuation of HCA Holdings Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| HIK.L - | HOLD | 0 @ GBP 20.2868 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 20.2868. The average price that HIK.L shares were previous bought at was GBP 22.6187. The current market price is -10.3% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 1,031 (USD $1,384) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.94843 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.94843. The average price that HLN.L shares were previous bought at was GBP 4.88757. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in HLN.L has increased by GBP 23,729 (USD $31,856) compared to the previous valuation of Haleon PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| HOLX - Hologic Inc | HOLD | 0 @ USD 74.93 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 74.93. The average price that HOLX shares were previous bought at was USD 70.9179. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in HOLX has fallen by USD 7,404 compared to the previous valuation of Hologic Inc |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 260.28 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 260.28. The average price that HUM shares were previous bought at was USD 265.443. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 39,144 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 260.28 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 260.28. The average price that HUM shares were previous bought at was USD 265.443. The current market price is -1.9% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 39,144 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 695.6 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 695.6. The average price that IDXX shares were previous bought at was USD 631.412. The current market price is 10.2% higher than average price they were purchased at. The value of the holding in IDXX has increased by USD 38,723 compared to the previous valuation of IDEXX Laboratories Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| ILMN - Illumina Inc | HOLD | 0 @ USD 129.56 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 129.56. The average price that ILMN shares were previous bought at was USD 110.231. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in ILMN has fallen by USD 6,814 compared to the previous valuation of Illumina Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 97.63 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 97.63. The average price that INCY shares were previous bought at was USD 103.304. The current market price is -5.5% lower than average price they were purchased at. The value of the holding in INCY has increased by USD 7,829 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 198.46 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 198.46. The average price that INSM shares were previous bought at was USD 200.537. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in INSM has fallen by USD 26,467 compared to the previous valuation of Insmed Inc |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 141.172 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 141.172. The average price that IPN.PA shares were previous bought at was EUR 136.726. The current market price is 3.3% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 1,737 (USD $2,041) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 221.43 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 221.43. The average price that IQV shares were previous bought at was USD 201.139. The current market price is 10.1% higher than average price they were purchased at. The value of the holding in IQV has fallen by USD 10,882 compared to the previous valuation of IQVIA Holdings Inc |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 556.86 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 556.86. The average price that ISRG shares were previous bought at was USD 539.91. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 58,845 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 210.33 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 210.33. The average price that JNJ shares were previous bought at was USD 172.38. The current market price is 22.0% higher than average price they were purchased at. The value of the holding in JNJ has increased by USD 164,891 compared to the previous valuation of Johnson & Johnson however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 255.81 | USD 0 | The current share valuation price of LH based on adjusted close was USD 255.81. The average price that LH shares were previous bought at was USD 262.154. The current market price is -2.4% lower than average price they were purchased at. The value of the holding in LH has fallen by USD 4,229 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1041.79 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1041.79. The average price that LLY shares were previous bought at was USD 871.319. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 870,262 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 659.241 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 659.241. The average price that LONN.SW shares were previous bought at was CHF 673.272. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 10,677 (USD $13,427) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 806.52 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 806.52. The average price that MCK shares were previous bought at was USD 786.762. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in MCK has fallen by USD 56,698 compared to the previous valuation of McKesson Corporation |
| MDT - Medtronic PLC | HOLD | 0 @ USD 98.3 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 98.3. The average price that MDT shares were previous bought at was USD 97.6582. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in MDT has increased by USD 20,845 compared to the previous valuation of Medtronic PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 99.18 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 99.18. The average price that MRK shares were previous bought at was USD 85.2551. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 167,868 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 99.18 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 99.18. The average price that MRK shares were previous bought at was USD 85.2551. The current market price is 16.3% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 167,868 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 140.29 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 140.29. The average price that MRK.DE shares were previous bought at was EUR 132.943. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in MRK.DE has fallen by EUR 6,317 (USD $7,422) compared to the previous valuation of Merck KGaA |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1384.68 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1384.68. The average price that MTD shares were previous bought at was USD 1459.22. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 4,358 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1384.68 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1384.68. The average price that MTD shares were previous bought at was USD 1459.22. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 4,358 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 141.7 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 141.7. The average price that NBIX shares were previous bought at was USD 143.035. The current market price is -0.9% lower than average price they were purchased at. The value of the holding in NBIX has fallen by USD 14,206 compared to the previous valuation of Neurocrine Biosciences Inc |
| NOVN.SW - | HOLD | 0 @ CHF 135.876 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 135.876. The average price that NOVN.SW shares were previous bought at was CHF 126.237. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 193,042 (USD $242,759) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 48.4779 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 48.4779. The average price that NOVO-B.CO shares were previous bought at was DKK 54.2313. The current market price is -10.6% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 79,988 (USD $12,580) compared to the previous valuation of Novo Nordisk A/S |
| NTRA - Natera Inc | HOLD | 0 @ USD 225.49 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 225.49. The average price that NTRA shares were previous bought at was USD 182.339. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in NTRA has fallen by USD 6,355 compared to the previous valuation of Natera Inc |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 71.3498 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 71.3498. The average price that ORNBV.HE shares were previous bought at was EUR 68.5395. The current market price is 4.1% higher than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 5,397 (USD $6,341) compared to the previous valuation of Orion Oyj |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.04 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.04. The average price that PFE shares were previous bought at was USD 24.8545. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in PFE has fallen by USD 132,153 compared to the previous valuation of Pfizer Inc |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 26.2831 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 26.2831. The average price that PHIA.AS shares were previous bought at was EUR 26.6032. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 4,629 (USD $5,439) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 145.189 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 145.189. The average price that PME.AX shares were previous bought at was AUD 174.833. The current market price is -17.0% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 7,884 (USD $5,230) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 289.57 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 289.57. The average price that PODD shares were previous bought at was USD 329.597. The current market price is -12.1% lower than average price they were purchased at. The value of the holding in PODD has increased by USD 2,672 compared to the previous valuation of Insulet Corporation however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 45.2313 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 45.2313. The average price that QIA.DE shares were previous bought at was EUR 45.7032. The current market price is -1.0% lower than average price they were purchased at. The value of the holding in QIA.DE has increased by EUR 48,138 (USD $56,560) compared to the previous valuation of QIAGEN NV however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 56.9623 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 56.9623. The average price that REC.MI shares were previous bought at was EUR 58.209. The current market price is -2.1% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 2,764 (USD $3,248) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 749.79 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 749.79. The average price that REGN shares were previous bought at was USD 715.253. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 24,696 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| RMD - ResMed Inc | HOLD | 0 @ USD 245.94 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 245.94. The average price that RMD shares were previous bought at was USD 255.221. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in RMD has fallen by USD 6,122 compared to the previous valuation of ResMed Inc |
| RO.SW - | HOLD | 0 @ CHF 411.805 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 411.805. The average price that RO.SW shares were previous bought at was CHF 347.062. The current market price is 18.7% higher than average price they were purchased at. The value of the holding in RO.SW has fallen by CHF 14,506 (USD $18,242) compared to the previous valuation of |
| ROG.SW - | HOLD | 0 @ CHF 399.094 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 399.094. The average price that ROG.SW shares were previous bought at was CHF 362.815. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in ROG.SW has fallen by CHF 180,136 (USD $226,529) compared to the previous valuation of |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 38.31 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 38.31. The average price that RPRX shares were previous bought at was USD 37.2888. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in RPRX has fallen by USD 624 compared to the previous valuation of Royalty Pharma Plc |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 96.528 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 96.528. The average price that SAN.PA shares were previous bought at was EUR 98.7753. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in SAN.PA has increased by EUR 73,046 (USD $85,825) compared to the previous valuation of Sanofi SA however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| SDZ.SW - | HOLD | 0 @ CHF 72.2925 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 72.2925. The average price that SDZ.SW shares were previous bought at was CHF 60.4305. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 11,412 (USD $14,351) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 14.8891 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 14.8891. The average price that SHL.AX shares were previous bought at was AUD 15.0907. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 8,144 (USD $5,403) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 52.472 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 52.472. The average price that SHL.DE shares were previous bought at was EUR 53.1451. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in SHL.DE has increased by EUR 3,328 (USD $3,910) compared to the previous valuation of Siemens Healthineers AG however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| SIG.AX - | HOLD | 0 @ AUD 1.94378 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.94378. The average price that SIG.AX shares were previous bought at was AUD 1.89939. The current market price is 2.3% higher than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 15,071 (USD $9,998) compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.3876 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.3876. The average price that SN.L shares were previous bought at was GBP 17.0453. The current market price is -3.9% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 3,884 (USD $5,214) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 35.116 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.116. The average price that SOBI.ST shares were previous bought at was SEK 33.1538. The current market price is 5.9% higher than average price they were purchased at. The value of the holding in SOBI.ST has increased by SEK 12,971 (USD $1,395) compared to the previous valuation of however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 79.95 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 79.95. The average price that SOLV shares were previous bought at was USD 74.1118. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in SOLV has fallen by USD 2,661 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 259.14 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 259.14. The average price that SOON.SW shares were previous bought at was CHF 270.65. The current market price is -4.3% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 24,230 (USD $30,470) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 277.994 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 277.994. The average price that SRT3.DE shares were previous bought at was EUR 260.473. The current market price is 6.7% higher than average price they were purchased at. The value of the holding in SRT3.DE has fallen by EUR 33,381 (USD $39,221) compared to the previous valuation of Sartorius AG |
| STE - STERIS plc | HOLD | 0 @ USD 251.67 | USD 0 | The current share valuation price of STE based on adjusted close was USD 251.67. The average price that STE shares were previous bought at was USD 244.356. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in STE has fallen by USD 47,530 compared to the previous valuation of STERIS plc |
| STMN.SW - | HOLD | 0 @ CHF 119.313 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 119.313. The average price that STMN.SW shares were previous bought at was CHF 121.328. The current market price is -1.7% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 1,110 (USD $1,396) compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 352.58 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 352.58. The average price that SYK shares were previous bought at was USD 368.927. The current market price is -4.4% lower than average price they were purchased at. The value of the holding in SYK has increased by USD 14,928 compared to the previous valuation of Stryker Corporation however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 30.06 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 30.06. The average price that TEVA shares were previous bought at was USD 20.8434. The current market price is 44.2% higher than average price they were purchased at. The value of the holding in TEVA has fallen by USD 1,000 compared to the previous valuation of Teva Pharma Industries Ltd ADR |
| TMO - Time Out Group plc | HOLD | 0 @ USD 562.56 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 562.56. The average price that TMO shares were previous bought at was USD 485.507. The current market price is 15.9% higher than average price they were purchased at. The value of the holding in TMO has fallen by USD 174,466 compared to the previous valuation of Time Out Group plc |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 276.348 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 276.348. The average price that UCB.BR shares were previous bought at was EUR 256.041. The current market price is 7.9% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 72,701 (USD $85,420) compared to the previous valuation of UCB SA |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 331.63 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 331.63. The average price that UNH shares were previous bought at was USD 322.008. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in UNH has fallen by USD 186,698 compared to the previous valuation of UnitedHealth Group Incorporated |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 510.941 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 510.941. The average price that UTHR shares were previous bought at was USD 437.623. The current market price is 16.8% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 10,667 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 215.46 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 215.46. The average price that VEEV shares were previous bought at was USD 270.663. The current market price is -20.4% lower than average price they were purchased at. The value of the holding in VEEV has fallen by USD 112,854 compared to the previous valuation of Veeva Systems Inc Class A |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 449.52 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 449.52. The average price that VRTX shares were previous bought at was USD 429.125. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 178,927 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| WAT - Waters Corporation | HOLD | 0 @ USD 377.12 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 377.12. The average price that WAT shares were previous bought at was USD 347.396. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 23,592 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 377.12 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 377.12. The average price that WAT shares were previous bought at was USD 347.396. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 23,592 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 269.13 | USD 0 | The current share valuation price of WST based on adjusted close was USD 269.13. The average price that WST shares were previous bought at was USD 265.622. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in WST has increased by USD 4,387 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 91.56 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 91.56. The average price that ZBH shares were previous bought at was USD 96.0496. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in ZBH has increased by USD 2,975 compared to the previous valuation of Zimmer Biomet Holdings Inc however if the holding was sold on 2025-12-17 this would crystalise an overall loss. |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 122.25 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 122.25. The average price that ZTS shares were previous bought at was USD 135.147. The current market price is -9.5% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 90,318 compared to the previous valuation of Zoetis Inc |